Study on the Improvement of Cardiac Function in Patients with Chronic Heart Failure Exacerbation Treated by Low-dose Sarcubatrix Valsartan  

作　　者：SHIXuewen ZANGXiumin 

机构地区：[1]The Fifth Medical Center of PLA General Hospital, Beijing 100071, China

出　　处：《外文科技期刊数据库(文摘版)医药卫生》2022年第9期206-210,共5页

摘　　要：Objective: to increase the use of low-dose sakubatroxvalsartan during routine treatment for patients with chronic heart failure who are in a state of aggravation, and to observe its actual efficacy. Methods: 120 patients with chronic heart failure were selected and randomly divided into two groups. Both groups were given drugs according to their conditions. The observation group was changed to low-dose sakubatrivalsartan after stopping ACEI/ARB. Results: the results in table 2-5 showed that the values in the observation group were more satisfactory (P0.05). Conclusion: for patients with chronic heart failure exacerbation, switching to low-dose sakubatroxvalsartan 36/24 hours after ACEI/ARB withdrawal can better reduce heart rate, blood pressure, neuroendocrine hormones, improve cardiac function, and do not increase serious adverse reactions without affecting the clinical efficacy.

关 键 词：low dose shakubatracvalsartan chronic heart failure aggravated cardiac function 

分 类 号：R541.6[医药卫生—心血管疾病]